Thrombophilie et occlusions vasculaires rétiniennes : une revue avec méta-analyse.

Titre original : 
Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta‐analysis.
Titre en français : 
Thrombophilie et occlusions vasculaires rétiniennes : une revue avec méta-analyse.
Auteurs : 
Romiti, GF, Corica, B, Borgi, M, et al.
Revue : 
J Thromb Haemost 2020; 18: 3249– 3266.




Résumé : 

Background

Retinal vascular occlusion is a leading cause of sight loss. Both retinal artery occlusion (RAO) and retinal vein occlusion (RVO) have been associated with hypercoagulable states; however, the burden of thrombophilia in these patients is unclear.

Objectives

This study aims at estimating the prevalence of inherited and acquired thrombophilias in adults with RAO or RVO through a systematic review and meta‐analysis of the literature.

Patients/Methods

PubMed and EMBASE were systematically searched from inception to 29 February 2020. All studies reporting prevalences of factor V Leiden (FVL) and prothrombin (F‐II) G20210A mutations, methylenetetrahydrofolate reductase (MTHFR) C677T and plasminogen activator inhibitor (PAI) 4G polymorphisms, antithrombin III (AT‐III), protein C (PC) and protein S (PS) activity deficiencies, hyperhomocysteinemia, and antiphospholipid (APL) antibodies in adults with RAO or RVO were included. Pooled prevalences and 95% confidence intervals (CI) were calculated.

Results

Ninety‐five studies were included; FVL and F‐II mutations were found in 6% (95% CI: 5‐8) and 3% (95% CI: 2‐4) of individuals with RVO, respectively, whereas AT‐III, PC, and PS activity deficiencies were found in <2%. The MTHFR C677T and PAI 4G homozygous polymorphism were observed in 13% (95% CI: 10‐17) and 23% (95% CI: 16‐31) of RVO, respectively; 8% presented APL antibodies. Similar findings were observed in individuals with RAO.

Conclusions

Compared with healthy subjects, patients with retinal vascular occlusion showed similar prevalences of inherited and acquired thrombophilias. These findings do not support routine thrombophilia screening in individuals with RAO or RVO.